Loading page
Loading page
Loading substance route
These combinations are considered extremely harmful and should always be avoided. Reactions to these drugs taken in combination are highly unpredictable and have a potential to cause death.
Early reports suggest 3-Cl-PCP is likely moderately addictive with habit-forming properties that may exceed those of other dissociatives such as ketamine, MXE, and DCK. Compulsive redosing is reported, particularly via smoked or vaporized routes of administration.
Cravings and withdrawal effects may occur upon cessation after chronic use, though specific physical withdrawal symptoms have not been characterized.
The exact toxic dosage is unknown. 3-Cl-PCP has an extremely brief history of human usage and its toxicity has not been studied in any scientific context.
Reports suggest 3-Cl-PCP produces cardiovascular effects including abnormal heartbeat, elevated blood pressure, and increased heart rate during intoxication, with sensations of cardiovascular strain as if the body is working harder to metabolize the substance; these effects appear more prominent than with related dissociatives.
Respiratory depression has been reported as a physical effect and may present increased risk at higher doses.
Repeated and excessive use over extended periods may cause bladder and urinary tract problems similar to ketamine-induced cystitis, though likely to a lesser extent due to the higher potency requiring smaller amounts of substance to be consumed.
Reports suggest a high potential for adverse psychological effects including psychosis and delusions. Risk appears elevated with chronic use or at higher doses.
Seizures may occur in individuals predisposed to them, especially in physically taxing conditions such as dehydration, fatigue, or malnourishment. The extent to which seizures occur at typical doses remains unknown.
3-Cl-PCP is a novel dissociative from the arylcyclohexylamine class that emerged as part of a wave of designer drugs in the early 2020s. It was first identified in Slovenia in December 2020, marking its initial appearance on the recreational drug market.…
Controlled substance under the Neue-psychoaktive-Stoffe-Gesetz (New Psychoactive Substances Act), which prohibits the production, distribution, and import of new psychoactive substances.
Not listed as a controlled substance as of 2021. However, legal status may have changed since this assessment.
Became a controlled substance in April 2021. Production, distribution, and possession are prohibited under national drug legislation.
Prohibited under the Psychoactive Substances Act 2016. It is illegal to possess, produce, supply, or import this substance.
8 sources cited